The short version of angiotensin IV fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-14 and is reviewed periodically as new material appears.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
proteinase Also endopeptidase or endoproteinase. Any enzyme that catalyzes the hydrolysis of peptide bonds more readily in intact, properly folded proteins than in small peptide molecules. Proteinases may be considered a subclass of proteases, though the terms are also often used interchangeably.
== Toxicity == The toxicity of organomercury compounds presents both dangers and benefits. Dimethylmercury in particular is notoriously toxic, but found use as an antifungal agent and insecticide. Merbromin and phenylmercuric borate are used as topical antiseptics, while thimerosal is safely used as a preservative for vaccines and antitoxins.
Nine people were killed in Russian missile attacks in Kharkiv. One person was killed in a separate attack in Donetsk Oblast. Russian-installed officials in Donetsk Oblast claimed that five people were killed in separate incidents of Ukrainian shelling. Ukraine launched Neptune missiles and drones at a ferry crossing and an oil depot in Port Kavkaz, Krasnodar Krai. Various sources reported three petroleum tanks were damaged and a fire broke out. Additional facilities at the Kavkaz port were damaged, including a train. A power substation connected to the Crimean Bridge was also damaged. Russian authorities claimed that two people were injured in the attack on the depot. The UAE brokered a prisoner swap in which 75 Ukrainians POWs were swapped for 75 Russian POWs. Following the US decision to allow it, German Chancellor Olaf Scholz also allowed Ukraine to use their weapons to attack targets in Russia. US sources claimed that the US government had handed over the "sensitive plans" for over 1,000 weapons systems for Ukraine to be able to build these weapons domestically. The Russian Justice Ministry designated the Put’ Domoi (Way Home) movement, a women's organisation composed of wives of Russians mobilised in Ukraine and advocating for their return on its list of "foreign agents", adding that the group was creating a "negative image" of Russia and its military and had called for illegal protests.
== Academic and scientific activities == A graduate of Ursinus College, Pennsylvania in 1986, Conway subsequently studied at the Burke Chemical Laboratories of Dartmouth College, New Hampshire, where he obtained his Ph.D. in 1991. His thesis concerned the attempted generation of indolyne (an aromatic compound related to indole). After college, Conway took a postdoctoral appointment in Chicago, later working as a contractor for the Food and Drug Administration, a researcher for Bionetics, a medicinal chemist for Avid Therapeutics (March 1995 – August 1997) and researcher for Message Pharmaceuticals (August 1997 – April 1999). He spent two years in organ distribution at the National Disease Research Interchange, and was subsequently employed by crop protection company Cerexagri as a regulatory chemist from May 2001 to June 2007, when he became a principal chemist for West Pharmaceutical Services. As of July 2013, he was working for a group near Raleigh, North Carolina. Conway has authored eleven professional publications and two patents. One patent covers compounds intended to treat hepatitis B in synergy with lamivudine; another relates to recyclable packaging material. His work has been published in Heterocycles, Synthetic Communications, Organic Preparations and Procedures International, Water Research, Rapid Communications in Mass Spectrometry, Antimicrobial Agents and Chemotherapy, Bioorganic & Medicinal Chemistry Letters and Current Organic Chemistry.
, the spreading slows down thus useful to set a prediction on the short-term trends. Also, it can be used to directly calculate the threshold population of vaccination/immunization for the herd immunity stage by setting
Sources: en.wikipedia.org
=== Revita === Revita is an outpatient endoscopic procedure that resurfaces the mucosal lining of the duodenum using ablation with water and heat. The duodenal lining can thicken with chronic high-fat and high-sugar diets; this can damage signaling mechanisms in the gastrointestinal tract and lead to metabolic disease. After resurfacing, a healthy mucosal layer can regrow over time, potentially improving blood sugar regulation and insulin sensitivity.
Found in the developing brain and certain adult brain regions such as the hippocampus. Neurodegeneration The progressive loss of structure or function of neurons, often leading to cell death. Seen in disorders such as Alzheimer’s disease and Parkinson’s disease. Neurodevelopment The biological processes through which the nervous system grows and matures, including neurogenesis, migration, synaptogenesis, and myelination. Neuroeconomics An interdisciplinary field that combines neuroscience, psychology, and economics to study decision-making and reward processing in the brain. Neuroepithelial cell A type of cell in the developing neural tube that gives rise to neural progenitor cells, which later differentiate into neurons and glia. Neuroethology The study of the neural basis of natural animal behavior, often involving model species and evolutionary comparisons. Neurofilament A type of intermediate filament found in neurons, important for maintaining cell shape and axonal transport. Neurofibrillary tangle A pathological hallmark of Alzheimer’s disease, composed of hyperphosphorylated tau protein that disrupts normal neuronal function. Neurogenesis The process by which new neurons are generated from neural stem or progenitor cells. Continues into adulthood in specific brain regions. Neuroglia Also known as glial cells, these support, protect, and nourish neurons. Types include astrocytes, oligodendrocytes, and microglia. Neuroimaging Techniques used to visualize the structure or function of the nervous system, including MRI, fMRI, PET, and EEG.
==== Type 1 ==== Ffar2 gene knockout mice (i.e., mice that have had their Ffar2 genes removed or inactivated) have decreased pancreatic beta cell masses at birth and throughout adulthood but do not develop diabetes. However, they do develop defective insulin secretion, glucose intolerance (a prediabetic condition in humans manifested by elevated blood glucose levels), and obesity. This mouse model has some but not all of the features found in human type 1 diabetes. In particular, human type 1 diabetes is at least partly a genetically predisposed autoimmune disease in which an individual's immune system causes inflammation in their pancreatic islets that injures their beta, alpha, and other cells. Non-obese Diabetic mice, i.e., NOD mice, may be a more appropriate model of the human disease. These mice are genetically predisposed to develop tissue-damaging inflammation in their pancreatic islets, insulin insufficiency, and overt diabetes. NOD mice fed a HAMSA or HAMSB diet (i.e., prebiotic diets which cause high intestinal levels of acetic acid or butyric acid, respectively), were partially protected and mice fed a combination of the two diets were fully protected from developing diabetes. Notably, Ffar2 gene knockout NOD mice had far more pancreatic islet inflammation and far less protection from becoming diabetic by either of these diets.
The human musculoskeletal system (also known as the human locomotor system, and previously the activity system) is an organ system that gives humans the ability to move using their muscular and skeletal systems. The musculoskeletal system provides form, support, stability, and movement to the body. The human musculoskeletal system is made up of the bones of the skeleton, muscles, cartilage, tendons, ligaments, joints, and other connective tissue that supports and binds tissues and organs together. The musculoskeletal system's primary functions include supporting the body, allowing motion, and protecting vital organs. The skeletal portion of the system serves as the main storage system for calcium and phosphorus and contains critical components of the hematopoietic system. This system describes how bones are connected to other bones and muscle fibers via connective tissue such as tendons and ligaments. The bones provide stability to the body. Muscles keep bones in place and also play a role in their movement. To allow motion, different bones form joints together. Cartilage prevents the bone ends from rubbing directly onto each other. Muscles contract to move the bones attached at the joint. The joints and muscles are designed to interact harmoniously so that any applied muscular force keeps the joint positioned and aligned correctly during movement and this, reciprocally, helps to maintain the correct length and tension in those corresponding muscles. There are, however, diseases and disorders that may adversely affect the function and overall effectiveness of the system.
Sources: en.wikipedia.org
Peroxisome proliferator-activated receptor gamma (PPAR-γ or PPARG), also known as the glitazone reverse insulin resistance receptor, or NR1C3 (nuclear receptor subfamily 1, group C, member 3) is a type II nuclear receptor functioning as a transcription factor that in humans is encoded by the PPARG gene.
== Epidemiology == Scleroderma most commonly first presents between the ages of 20 and 50 years, although any age group can be affected. Women are four to nine times more likely to develop scleroderma than men. This disease is found worldwide. In the United States, prevalence is estimated at 240 per million, and the annual incidence of scleroderma is 19 per million people. Likewise, in the United States, it is slightly more common in African Americans than in their white counterparts. Choctaw Native Americans are more likely than Americans of European descent to develop the type of scleroderma that affects internal organs. In Germany, the prevalence is between 10 and 150 per million people, and the annual incidence is between three and 28 per million people. In South Australia, the annual incidence is 23 per million people, and the prevalence 233 per million people.
=== Succinate-CoA ligase === Succinate-CoA ligase is a heterodimer composed of an invariant α-subunit and a substrate-specific ß-subunit, encoded by either SUCLA2 or SUCLG2. This combination results in either an ADP-forming succinate-CoA ligase (A-SUCL, EC 6.2.1.5) or a GDP-forming succinate-CoA ligase (G-SUCL, EC 6.2.1.4). The ADP-forming succinate-CoA ligase is potentially the only matrix enzyme generating ATP in the absence of a proton motive force, capable of maintaining matrix ATP levels under energy-limited conditions, such as transient hypoxia.
The army throughout the spring of 1943 was significantly reinforced and grew to a strength of 1,100 tanks and 250,000 men by July 1943. It was to form the southern spearhead in the Battle of Kursk. The army tried but failed to break through the Soviet defences around Kursk. It then fought a series of defensive battles throughout the remainder of 1943 to hold back the Red Army's Lower Dnieper Strategic Offensive Operation. By November 1943, the Soviets had reached Kiev and the 4th Panzer Army was tasked to defend the city. The Soviet aim was to take the city and break the rail link with Army Group Center or envelop Army Group South. But even though the Soviets had liberated Kiev, broken the Dnieper line, and inflicted massive casualties, the 4th Panzer Army held on and the Soviets failed to break the rail link.
A base and an acid, e.g., NaOH + HCl → NaCl + H2O A metal and an acid, e.g., Mg + H2SO4 → MgSO4 + H2 A metal and a non-metal, e.g., Ca + Cl2 → CaCl2 A base and an acid anhydride, e.g., 2 NaOH + Cl2O → 2 NaClO + H2O An acid and a base anhydride, e.g., 2 HNO3 + Na2O → 2 NaNO3 + H2O An acid anhydride and a base anhydride, e.g., CO2 + Na2O → Na2CO3 In the salt metathesis reaction where two different salts are mixed in water, their ions recombine, and the new salt is insoluble and precipitates. For example: Pb(NO3)2 + Na2SO4 → PbSO4↓ + 2 NaNO3
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.